Real‐world retention of newer ASMs , including lacosamide and brivaracetam as first or second therapies in adult‐onset epilepsy

Documenti analoghi

• Value of drug level concentrations of brivaracetam, lacosamide, and perampanel in care of people with epilepsy
  di: Matthias Hentschel, et al.
  Pubblicazione: (2024)
• Short‐term sick leave due to epilepsy in the Swedish Prospective Regional Epilepsy Database and Biobank for Individualized Clinical Treatment (PREDICT)
  di: Kerstin Andrén, et al.
  Pubblicazione: (2025)
• Cardiovascular risk factor assessment in late‐onset seizures: A study protocol to assess the value of structured intervention
  di: David Larsson, et al.
  Pubblicazione: (2024)
• The cenobamate KORK study—A prospective monocenter observational study investigating cenobamate as an adjunctive therapy in refractory epilepsy, with comparisons to historical cohorts treated with add‐on lacosamide, perampanel, and brivaracetam
  di: Bernhard J. Steinhoff, et al.
  Pubblicazione: (2024)
• S100 calcium‐binding protein beta (S100B) in serum as a biomarker for epilepsy after traumatic brain injury: A register‐based cohort study in Danish adults
  di: Kasper Lolk, et al.
  Pubblicazione: (2025)